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The rate of hepatocellular carcinoma (HCC) is increasing worldwide including Egypt. Non-B non-C HCC was reported in
some countries. We aimed to investigate P53 antibodies and alpha-fetoprotein in patients with non-B non-C HCC in our
region. In a case series study, included 281 patients with HCC and 20 patients with liver cirrhosis of matched age, sex and
social factors were received for management at Tanta University Hospitals. Sera were tested for HCV and HBV markers by
ELISA/PCR, alpha-fetoprotein (AFP) level and anti-p53 antibody were evaluated by ELISA. Antinuclear antibody, serum
copper and iron were assessed in non-viral HCC. Liver scanning and biopsy were evaluated. Non-B non-C HCC patients
were 13.87% of total. P53 antibody serum level in non-B non-C HCC patients showed insignificant difference (p>0.05) as
compared to viral-associated HCC, while significant as compared to cirrhosis. They had significant decrease in serum AFP
level (p<0.001) as compared to viral-associated HCC. Their tumors were mainly solitary, and have smaller-sizes. Sensitivity,
specificity, PPV, NPV and accuracy test of anti P53 antibody positive patients were 91.52%, 84.63%, 90.34%, 80.2% and
74.8% respectively. It correlates positively with AFP, tumor size and staging, MELD score and Child-Pugh score.
Non-B non-C HCC showed high serum prevalence of anti-p53 as viral-associated HCC suggesting an evidence of high
onchogenecity. It appears of much benefit in diagnosis, follow up and differentiation from cirrhosis in presence of low
levels of alpha-fetoprotein.
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There is a heterogeneous distribution of HCC at regional
and international levels due to infectious and/or environ-
mental factors that may contribute to risk (Lehman et al.
2007). Egypt has the highest prevalence of HCV worldwide
and has rising rates of HCC (Lehman and Wilson 2009).
The major risk factors include chronic HBV and HCV
infections and chemical exposures (Wang et al. 2002,
and Ertle et al. 2010). Recently, the proportion of non-B
non-C HCC has been increasing in many areas of the
world (Ertle et al. 2010). The pattern of HCC and its risk
factors is changing (Anwar et al. 2008).
The p53 protein is involved in DNA repair and is an
oncoprotective antigen. This gene when damaged, leads* Correspondence: aaboalazm@gmail.com
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reproduction in any medium, provided the origto production of anti-p53 and predisposes to various
cancers, including HCC (Di Cesare et al. 2001, and
Ndububa et al. 2001).
P53 antibodies are predominantly associated with p53
gene mutations (Soussi 2000) in the sera of patients with
various types of cancer (Shimada et al. 2003). It was
reported with high titration in viral-associated HCC
Egyptian patients (Atta et al. 2008).
Due to the alarming increase in the incidence of HCC,
there is a need for recent insights on contribution of
emerging risk factors of hepatocellular carcinogenesis
(Abdel-Hamid 2009), and provide more effective measures
for early diagnosis, monitor progress and intervention.
We aimed to determine prevalence and diagnostic util-
ity of P53 antibodies and alpha fetoprotein in patients
with non-B non-C HCC in our region.his is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Abou El Azm et al. SpringerPlus 2013, 2:69 Page 2 of 6
http://www.springerplus.com/content/2/1/69Patients and methods
Patients
In a case series retrospective study, included 281
patients with HCC were received for management at
Tanta University Hospitals, within the last 3 years (from
March 2009 to February 2012) and twenty patients with
cirrhosis, and without any evidence of HCC as control,
with matched age, sex, and social factors.
Study area
(Gharbia Governorate): The residence area of patients is
generally a rural area containing villages and districts;
most people are working in agriculture, and the area is
highly endemic with HCV, and to a lesser extent HBV.
This area has important chemical industrial factories in
Kafr El-Zayat district, where unfortunately non-B non-C
HCC patients were received.
Methods
All patients were subjected to: History taking included
demographic variables, and environmental exposures.
Clinical assessment and diagnosis of HCC was based on
detection of hepatic focal lesions by imaging techniques
(ultrasonography with, or without triphasic CT scans)
plus serum alpha-fetoprotein (Sorin Biomedica - 3rd
generation ELISA) and guided liver & tumor biopsy for
histopathological confirmation. Tumor staging was done
according to Llovet, et al. (1999).
Serological investigations for viral etiology
Sera were tested for HCV antibody (Qualitest HCV-3rd
generation ELISA) confirmed by RT-PCR using the
automated Cobas Amplicor system of Roche. HBV infec-
tion was assessed using: HBs Ag and HBc Ab IgG (in
negative HBs Ag) by 3rd generation ELISA, and HBV-
DNA for patients with negative HBs Ag and HBc Ab
IgG using the automated Cobas Amplicor system of
Roche.
Serum total iron binding capacity, ceruloplasmin, and
antinuclear antibody, were evaluated for the etiology of
HCC patients.
Anti-p53 antibodies were evaluated by a modified
ELISA test (Atta et al. 2008) to estimate the levels in
sera of HCC patients and control groups, as a modifica-
tion of Engvall and Perlmann (1971).
The procedure in brief is as follows
Polystyrene microtiter plates (Nunc Maxisorp, flat bot-
tom) were coated with 100 μL of recombinant wild-type
human p53 protein (Sigma Chemical Company, USA) in
the concentration of 5 μg/mL in Carbonate buffer, 0.06
M, pH 9.6. The coated plate was incubated overnight at
room temperature under humidified atmosphere. The
plates were washed four times with phosphate bufferedsaline (PBS) containing 0.1% Tween 20 (PBS-T). The
non-specific sites in the wells were blocked with 0.2%
non-fat milk for 2 hours at 37°C. After 4 washes with
PBS-T, the plates were incubated with 1:1000 dilutions
of the sera from patients and control groups. After 2
hours incubation at 37°C and washing, anti-human IgG
whole molecule alkaline phosphatase conjugate (Sigma
Chemical company, USA), at dilution 1:500 in PBS-T
containing 0.2% non-fat milk, was added as the second-
ary antibody. At the end of 2 hours incubation at 37°C
and washing, the color was developed by the addition of
100 μL of the substrate, para-nitrophenyl phosphate
(Sigma Chemical Company, USA) to each well. After
arresting the reaction with 50 μL of 3 N HCl, the op-
tical density reading was taken in the microplate spec-
trophotometer (EL311 microplate autoreader, Bio-Tek
instruments, USA) at 405 nm wave length. Cutoff level
of ELISA above or below which the tested samples were
considered positive or negative was calculated as the
mean concentration using 0.04 OD cutoff points.
The study was approved by the Ethical and Research
Committee of Tanta Faculty of Medicine and an informed
consent was taken from each participant.
Statistical analysis
Was performed by the statistical software SPSS 11 using
independent-sample t test. Chi-square was applied for
the results. P < 0.05 was considered statistically signifi-
cant, and < 0.001 highly significant. Analysis of variance
[ANOVA] tests by SPSS V.16. Linear Correlation Coeffi-
cient [r] of the results was carried out.
Results
Serum total iron binding capacity, ceruloplasmin, and
antinuclear antibody were detected in average values in
non-B non-C HCC patients.
Table 1 showed: Non-B non-C ratio in HCC patients
were 39/281 = 13.87%, HCV were 186/281 =66.19%,
HBV were 26/281 = 9.25% and HCV/HBV co-infection
29/281 = 10.32%. There is a rising incidence per year
without significant difference P > 0.05.
Table 2 showed: The frequency of anti-p53 antibodies
using a cutoff point of 0.4 OD in viral-associated HCC
patients, were positive in 168 of 242 (69.42%), non-B
non-C HCC in 26 of 39 (66.66%) and liver cirrhosis
in 4 of 20 patients (20%). No significant difference
was detected between all groups as regard to age, and six
(p > 0.05). Serum level of P53 antibodies in non-B non-C
HCC patients showed insignificant difference (p > 0.05)
as compared to viral-associated HCC, while significant as
compared to cirrhosis. They had significant decrease in
serum alpha-fetoprotein level (p < 0.001) as compared to
viral-associated HCC. Their tumors were mainly solitary
and have smaller-sizes.
Table 1 Number of viral and non-viral HCC patients and ratios/ year
Number in Years Viral (HCV, HBV and co-infect.) Non-B non-C Total
- First year 74 (C: 57, B: 10, C&B: 7) =30.58% 5 =12.82% 79 =28.11%
- Second year 83 (C: 62, B: 10, C&B:11) =34.30% 10 =25.64% 93 =33.10%
- Third year 85 (C: 67, B: 6, C&B:12) =35.12% 24 = 61.54% 109 =37.79%
Total in 3 years 242 (C: 186, B: 26, C&B:30) = 100% 39 = 100% 281 = 100%
There is insignificant increase in number of total HCC, viral, non-viral HCC patients when comparing between first, second and third year (P-Value >0.05).
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 Class A (X2 1 = 11.69, X2 2 = 1.45, X2 3 = 9.15).
There was a significant increase in non-B non-C
HCC group when compared to viral group.
 Class B (X2 1 = 0.22, X2 2 = 2.56, X2 3 = 0.95)
 Class C (X2 1 = 13.8, X2 2 = 0.033, X23 = 6.12). There
was a significant increase in viral group when
compared to non-B non-C group.Table 2 Liver grading, tumors features, AFP and anti P53 find
Items Viral (n = 242) Non-B
Age (years) 51.9 ± 11.7 5
Gender:
- Male 185(76.45%) 37
- Female 57(23.55%) 2
Severity of liver disease: Child-Pugh score
- Class A 80(33.06%) 24
- Class B 48(19.83%) 9
- Class C 114(47.11%) 6
(MELD score)
- Early (6-11) 48(19.83%) 23
- Intermed.(12-18) 84(34.71%) 10
- Sever (19-40) 110(45.45%) 6
Anti P53 antibody + ve 168(69.42%) 26
AFP (ng/mL)
- <200 52(21.48%) 31
- 200-500 84(34.71%) 5
- >500 106(43.80%) 3
Tumor findings US/CT
Size (cm):






Significant* P value < 0.05 Highly Significant * P value < 0.001.
P1 = viral vs. non-viral group P2 = viral vs. cirrhosis group.
P3 = non-viral vs. cirrhosis group.Table 3: showed: Sensitivity, specificity, PPV, NPV
and accuracy test of anti P53 antibody positive
patients were 91.52%, 84.63%, 90.34%, 80.2% and
74.8% respectively.
Table 4: showed significantly positive correlations of
P53 antibody with AFP, tumor size, tumor number,
MELD score, Child-Pugh score, and Tumor staging.
Figure 1: showed CT scan with HCC in both lobes of
liver of variant size while Figures 2 and 3 showed posi-
tive correlations of P-53 antibody with alpha fetoproteinings in patient groups
nonC (n = 39) Cirrhosis (n = 20) P1 P2 P3
5.5 ± 6.2 53.1 ± 95 >0.05 >0.05 >0.05
(94.87%) 15(75.00%) >0.05 >0.05 >0.05
(05.13%) 4(20.00%) >0.05 >0.05 >0.05
(61.54%) 4(20.00%) < 0.05* >0.05 >0.05
(23.08%) 7(35.00%) >0.05 >0.05 >0.05
(15.38%) 9(45.00%) < 0.05* >0.05 >0.05
(58.97%) 3(15.00%) <0.001* >0.05 <0.05*
(25.64%) 8(40.00%) >0.05 >0.05 >0.05
(15.38%) 9(55.00%) < 0.05* >0.05 >0.05
(66.66%) 4(20.00%) >0.05 < 0.05* <0.05*
(79.49%) 20(100%) <0.001* <0.001* >0.05
(12.82%) - >0.05 < 0.05* >0.05
(07.69%) - < 0.05* < 0.05* >0.05
(66.66%) - <0.001* - -
(23.08%) - >0.05 - -
(10.26%) - < 0.05* - -
(84.62%) - >0.05 - -
(15.38%) - >0.05 - -
Table 3 Sensitivity, Specificity, PPV, NPV and Accuracy
test of anti P53 antibody + ve patients
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tumor size in non-B non-C HCC respectively.Figure 1 Showing CT scan with HCC of variant size in both
lobes of liver.Discussion
Chronic HBV, and HCV, are the most important risk
factors in the development of HCC (Tornai 2010) in
agreement with the present results. Egypt has the
highest prevalence of HCV worldwide, and has rising
rates of HCC (Lehman and Wilson 2009). Prevalence of
HBV, and HCV were reported 25.9%, and 78.5% among
HCC cases respectively (Severi et al. 2010).
HCC in previous studies confirmed wide international
variation risks (Franceschi and Raza 2009). Multiple
non-viral factors have been implicated in the develop-
ment of HCC (Soliman et al. 2010). Approximately, 10%
of HCC patients were reported negative for both HBV
markers and antibodies to HCV (Kusakabe et al. 2007).
In the current work, a higher rate 13.87% of non-B non-
C was detected, while Abe et al. (2008) reported increas-
ing ratio from 17.8% in 2000 to 28.6% in 2006 in Japan.
This difference in prevalence, between Egypt, and Japan
could be attributed to the difference in environmental
risks, and the higher prevalence of HCV in Egypt.
In the current study, no significant difference was
detected between non-B non-C HCC, and those of viral-
association, as regard to age, or gender in agreement
with previous reports (Asahina et al. 2010, and Yeh and
Chen 2010). Some difference could be attributed to the
nature of work making men more exposed to more risks,
and/or the intensity of these risks.Table 4 Correlations of P-53 antibody with AFP, tumor
size, tumor number, MELD score, Child-Pugh score, and
Tumor staging
P-53 antibody Non-B non-C Viral-associated
r. p. value r. p. value
AFP (ng/mL) 0.704 0.001 0.880 0.001
Tumor Size (cm) 0.829 0.001 0.896 0.001
Tumor Number 0.573 0.001 0.815 0.001
MELD score 0.790 0.001 0.848 0.001
Child-Pugh score 0.764 0.001 0.810 0.001
Tumor stage 0.856 0.01 0.472 0.003According to our knowledge, there are no previous
reports for non-B non-C HCC in our region, but reports
of exposure to chemicals in HCV-associated HCC were
reported. Chemicals can induce hepatic carcinogenesis
through direct hepatotoxicity, inducing oxidative stress,
and/or causing steatohepatitis (Angulo 2002), which
seems to have a cumulative effect.
In our study, serum total iron binding capacity,
ceruloplasmin, and antinuclear antibody were detected
in average values in non-B non-C HCC patients. This
could exclude the role of iron, copper and auto immun-
ity in hepatic carcinogenesis of this group.
In the current study, anti-p53 showed insignificant dif-
ference between both HCC groups of patients,
suggesting the presence of non-viral onchogens in non-
B non-C HCC patients. This could agree with previous
results, with high percentage of positivity of anti-p53
antibodies in Egyptian healthy subjects (Attallah et al.
2009, and Gadelhak et al. 2009). They mentioned thatFigure 2 Correlation of P-53 antibody with alpha fetoprotein in
non-B non-C HCC group.
Figure 3 Correlation of P-53 antibody with tumor size in non-B
non-C HCC group.
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hepatic carcinogenesis. The finding of P53 antibodies in
sera of individuals who are at high risk of cancer, as
workers exposed to chemicals indicates that they have
onchogenic potential, and promising in the early detec-
tion of cancer. Expressions were more pronounced in
patients with HCC more than patients with liver cirrho-
sis, which could be of clinical importance for early diag-
nosis. This could be explained by interactions of
chemical carcinogens, and genetic variations, are pos-
sible in HCC (Zhang 2010).
Alpha fetoprotein showed significantly lower levels in
non-B non-C HCC, as compared to patients with viral-
associated HCC in agreement with a previous report
(Yamagishi et al. 2004), as tumors were detected of al-
most solitary, and of small sizes. High ratios of sensitiv-
ity, specificity, PPV, NPV and accuracy test of anti P53
antibody positive patients which could suggest clinical
significance in non-B non-C HCC patients.Conclusion
The study revealed that HCC increasing rate is not only
due to high endemicity of HCV and/or HBV but also
due to non-B non-C environmental risks. Low serum
alpha-fetoprotein level in non-B non-C HCC may add a
difficulty in screening of these patients. The high preva-
lence of serum anti-p53 in our study could suggest evi-
dence of high onchogenicity and could be of help in
diagnosis and intervention in presence of low levels of
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